- Posted in Business Critical | August 02, 2012 | Comments (0)
- Tags: earnings, financial, company financials, sales
- By: Julie A. Vetalice
Page 1 of 8
ORTHOWORLD’s estimates place overall 1Q12 market growth at 4% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise.
Exhibit 1: Orthopaedic Sales Increases1 by Product Segment: 1Q12 vs. 1Q11
NOTES TO EXHIBIT 1
- Orthopaedic products; constant currency, pro forma growth
- Includes biologics
- For the quarter ended 2/29/12; includes Dental. Spine includes Bone Stim and Biologics; Bone Stim reflects all Bone Healing sales.
- For the quarter ended 4/27/12
- Spine
- For the quarter ended 3/31/12
- Extremities: extremities + fixation combined; Endoscopy: endoscopic + communications, most of which is orthopaedic; Spine: neuro + spine. Total growth excludes Patient Handling.
- ORTHOWORLD estimates
- For the quarter ended 3/31/12
